LAURENT LEVY

About LAURENT LEVY

Laurent Lévy is the co-founder of Nanobiotix, the French listed biotechnology company focused on nanomedicine-based approaches for oncology. He has served as Chief Executive Officer since 2003 and was first appointed Chairman of the Executive Board in 2004. His career is closely tied to the creation and growth of Nanobiotix, which he has helped build from an early-stage scientific venture into an internationally recognized company working on radioenhancement technologies and innovative cancer treatment solutions. Before founding Nanobiotix, Lévy worked as a consultant at Altran Technologies and contributed to nanotechnology development projects for companies including Sanofi, Guerbet, and Rhodia, as well as other early-stage biotechnology businesses. This background gave him a rare combination of scientific depth and industrial exposure, spanning breakthrough innovation, technology transfer, and corporate strategy. He has also held governance responsibilities, including serving as Chairman of the Supervisory Board of Valbiotis and as Vice Chairman of the European Technology Platform on Nanomedicine (ETPN). He holds a doctorate in physical chemistry, specializing in nanomaterials, from Pierre and Marie Curie University and the CEA, and completed a postdoctoral fellowship at the University at Buffalo. His scientific profile is reflected in more than 35 publications, several patent applications and grants, and regular contributions to international discussions on nanomedicine and oncology. At Nanobiotix, Lévy has played a central role in shaping a research-driven company, advancing its clinical programs, and positioning it for scientific and industrial partnerships. His leadership is commonly associated with the combination of scientific excellence, global ambition, and long-term value creation in the life sciences sector.